Novotný M, Kostrica R, Círek Z
Department of Otolaryngology, University Hospital, Brno-Bohunice, Czech Republic.
Int Tinnitus J. 1999;5(1):60-2.
We were interested in determining the efficacy of Arlevert therapy in vertigo and tinnitus patients, especially as it compared to the efficacy of the drug's two component agents, dimenhydrinate and cinnarizine. We conducted a comparative, randomized, double blind, multicenter, parallel group study involving a group of patients (n = 122) with vertigo and tinnitus of peripheral or central origin. The three test groups, nearly equal in size, were administered three times daily for 4 weeks one of the three agents being evaluated. To evaluate therapeutic success, we studied patients' vertigo symptoms, concomitant vegetative symptoms, CCG parameters, and electronystagmographic and audiometric parameters. We also obtained subjective assessments of outcomes from the test patients. Our results led us to conclude that Arlevert is more effective than either of its component drugs alone in treating vertigo and tinnitus. The drug also was well tolerated.
我们旨在确定阿乐维特疗法对眩晕和耳鸣患者的疗效,尤其是将其与该药物的两种成分——茶苯海明和桂利嗪的疗效进行比较。我们开展了一项对比、随机、双盲、多中心、平行组研究,纳入了一组患有外周性或中枢性眩晕和耳鸣的患者(n = 122)。三个试验组规模相近,分别每日给药三次,持续4周,给予三种待评估药物中的一种。为评估治疗效果,我们研究了患者的眩晕症状、伴随的自主神经症状、CCG参数、眼震电图和听力测定参数。我们还从受试患者那里获得了对治疗结果的主观评估。我们的结果使我们得出结论,在治疗眩晕和耳鸣方面,阿乐维特比其任何一种单一成分药物都更有效。该药物耐受性也良好。